• Improving Patient 
    Outcomes in
    Solid Tumor
    Cancer Treatment

    BIO300
    A New Class of Cancer Drug

  • Keeping America Safe

    BIO300
    Protecting Civilians, First Responders and Our Military
    from Nuclear Accidents and Terrorism

Oncology

BIO 300 improves outcomes for cancer patients receiving radiation treatments.

BIODEFENSE

BIO 300 prevents and mitigates acute and delayed radiation injuries from nuclear accidents or acts of terrorism.

Humanetics News

10.23.18

Humanetics Corporation to Present at Annual Meeting of Society for Radiation Oncology
Read More

10.8.18

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference
Read More

09.25.18

Humanetics Corporation Presents Data on BIO 300 at Radiation Research Society Annual Meeting
Read More

07.17.18

Humanetics Corporation Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Injury
Read More

04.12.18

Humanetics Corporation Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs
Read More

02.12.18

Humanetics Corporation Presents at 2018 BIO CEO and Investor Conference
Read More

01.30.18

Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity From Space-Like Radiation

Read More

01.11.18

Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board

Read More

10.31.17

Humanetics Presents Data for Cancer Drug

Read More

10.10.17

Humanetics Receives New Grant from NASA

Read More

09.26.17

Humanetics Receives $3.8 Million Grant from Department of Defense

Read More

09.12.17

Humanetics Receives Patent for Cancer Drug

Read more

08.22.17

Humanetics to Present at Department of Defense Scientific Meeting

Read more